Maze Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good morning and thank you for joining us today. My name is Elizabeth Webster. I'm on the biotechnology equity research team here at Goldman Sachs. And today, we have with us Jason Coloma, the CEO of Maze Therapeutics. Thank you, Jason, for being with us.
Questions & Answers
I guess to start, can you provide an introduction to the company and walk us through where Maze stands today with your lead assets, 828 in AMKD and 782 in PKD and CKD?
Yes. Well, thanks for having me today. Yes. So we are, if you will, a small molecule precision medicines company really focused on diseases that really haven't seen precision before like kidney disease. There's over 800 million people in the world that suffer from kidney disease. It's the ninth leading cause of death globally.
In some countries, there's a four-year waiting list for, if you will, a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
